Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00824434
NCT00824434CompletedPhase 3

A Prospective, Multi-center Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™)

Boston Scientific Corporation17 sites in 4 countries100 target enrollmentStarted: March 1, 2009Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions

Trial Snapshot

Phase
Phase 3
Status
Completed
Enrollment
100
Locations
17
Primary Endpoint
Cardiac Events (Composite)
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Compile acute (30-day) clinical outcomes data and 9-month angiographic and intravascular ultrasound (IVUS) data for the PROMUS Element™ Everolimus- Eluting Coronary Stent System in the treatment of patients with a single de novo atherosclerotic lesion

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patient (or legal guardian) understands the study requirements and the treatment procedures and provides written informed consent before any study-specific tests or procedures are performed
  • •Patient is eligible for percutaneous coronary intervention (PCI)
  • •Patient has documented stable angina pectoris (Canadian Cardiovascular Society [CCS] Classification 1, 2, 3, or 4) or documented silent ischemia; or unstable angina pectoris (Braunwald Class IB-C, IIB-C, or IIIB-C)
  • •Patient is an acceptable candidate for coronary artery bypass grafting (CABG)
  • •Patient has a left ventricular ejection fraction (LVEF) >=30% as measured within 30 days prior to enrollment
  • •Patient is willing to comply with all specified follow-up evaluations
  • •Angiographic Inclusion Criteria:
  • •Target lesion must be a de novo lesion located in a native coronary artery with visually estimated diameter of >=2.25 mm and <=4.25 mm
  • •Target lesion length must measure (by visual estimate) <=34 mm
  • •Target lesion must be in a major coronary artery or branch with visually estimated stenosis >=50% and <100% with Thrombolysis in Myocardial Infarction (TIMI) flow >1.

Exclusion Criteria

  • •Patient has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute myocardial infarction (MI)
  • •Patient has had a known diagnosis of recent MI (within 30 days prior to the index procedure) and has elevated enzymes at the time of the index procedure as follows.
  • •Patients are excluded if any of the following criteria are met at the time of the index procedure
  • •If creatine kinase, MB band (CK-MB) >2× upper limit of normal (ULN), the patient is excluded regardless of the creatine kinase (CK) Total.
  • •If CK-MB is 1-2× ULN, the patient is excluded if the CK Total is >2× ULN.
  • •If CK Total/CK-MB are not used and Troponin is, the patients are excluded if the following criterion is met at the time of the index procedure.
  • •Troponin >1× ULN with at least one of the following.
  • •Patient has ischemic symptoms and electrocardiogram (ECG) changes indicative of ongoing ischemia (e.g., >1mm ST segment elevation or depression in consecutive leads or new left bundle branch block [LBBB]);
  • •Development of pathological Q-waves in the ECG
  • •Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
  • •Note: For patients who have had a recent MI, CK Total/CK-MB (or Troponin if CK Total/CK-MB are not used) must be documented prior to enrolling the patient
  • •Patient has received an organ transplant or is on a waiting list for an organ
  • •transplant
  • •Patient is receiving or scheduled to receive chemotherapy within 30 days before or after the index procedure
  • •Patient is receiving oral or intravenous immunosuppressive therapy (ie, inhaled steroids are not excluded) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus, but not including diabetes mellitus)
  • •Patient is receiving chronic (>=72 hours) anticoagulation therapy (eg, heparin, coumadin) for indications other than acute coronary syndrome
  • •Patient has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3
  • •Patient has a white blood cell (WBC) count <3,000 cells/mm3
  • •Patient has documented or suspected liver disease, including laboratory evidence of hepatitis
  • •Patient is on dialysis or has known renal insufficiency (i.e., estimated creatinine clearance <50 mL/min by the Cockcroft Gault formula, ie [(140-age)*lean body weight (in kg)]/[plasma creatinine (mg/dL)*72])
  • •Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions
  • •Patient has had a cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months, or has any permanent neurologic defect that may cause non-compliance with the protocol
  • •Target vessel or side branch has been treated with any type of percutaneous coronary intervention (PCI; eg, balloon angioplasty, stent, cutting balloon, atherectomy) within 12 months prior to the index procedure
  • •Target vessel has been treated within 10 mm proximal or distal to the target lesion (by visual estimate) with any type of PCI (eg, balloon angioplasty, stent, cutting balloon, atherectomy) at any time prior to the index procedure
  • •Non-target vessel or side branch has been treated with any type of PCI (eg, balloon angioplasty, stent, cutting balloon, atherectomy) within 24 hours prior to the index procedure
  • •Planned or actual target vessel treatment with an unapproved device, directional or rotational coronary atherectomy, laser, cutting balloon or transluminal extraction catheter immediately prior to stent placement
  • •Planned percutaneous coronary intervention or coronary artery bypass grafting after the index procedure
  • •Patient previously treated at any time with coronary intravascular brachytherapy
  • •Patient has a known allergy to the study stent system or protocol-required concomitant medications (e.g., stainless steel, platinum, cobalt, chromium, nickel, tungsten, acrylic, fluoropolymers, everolimus, thienopyridines, aspirin, contrast) that cannot be adequately premedicated
  • •Patient has active peptic ulcer or active gastrointestinal (GI) bleeding
  • •Patient has one of the following:
  • •Other serious medical illness (eg, cancer, congestive heart failure) that may reduce life expectancy to less than 24 months
  • •Current problems with substance abuse (eg, alcohol, cocaine, heroin, etc.)
  • •Planned procedure that may cause non-compliance with the protocol or confound data interpretation
  • •Patient is participating in another investigational drug or device clinical trial that has not reached its primary endpoint
  • •Patient intends to participate in another investigational drug or device clinical trial within 12 months after the index procedure
  • •Known intention to procreate within 12 months after the index procedure
  • •Female with positive pregnancy test within 7 days prior to the index procedure (a pregnancy test must be performed in women of child-bearing potential prior to enrollment), or lactating
  • •Patient has more than 1 target lesion or more than 1 target lesion and 1 non-target lesion, identified during screening for intervention
  • •Angiographic Exclusion Criteria:
  • •Target lesion meets any of the following criteria:
  • •Aorto-ostial location (i.e., lesion located within 5 mm of the ostium)
  • •Left main location
  • •Located within 5 mm of the origin of the left anterior descending (LAD) coronary artery or left circumflex (LCX) coronary artery
  • •Located within a saphenous vein graft or an arterial graft
  • •Can only be accessed via a saphenous vein graft or an arterial graft
  • •Involves a side branch >=2.0 mm in diameter
  • •Involves a clinically significant side branch <2.0 mm in diameter that has a clinically significant stenosis at the ostium
  • •TIMI flow 0 (total occlusion) or TIMI flow 1 prior to wire crossing
  • •Excessive tortuosity proximal to or within the lesion
  • +5 more not shown

Arms & Interventions

Experimental Stent

Experimental

Intervention: PROMUS Element™ (Device)

Outcomes

Primary Outcomes

Cardiac Events (Composite)

Time Frame: 30 days

Percentage of patients who had a myocardial infarction, cardiac death, target lesion revascularization, or stent thrombosis (defined as definite or probable per the Academic Research Consortium \[ARC\] definitions); see below for definitions of individual components.

Secondary Outcomes

  • In-stent Late Loss(9 months)
  • Occurance of Post-procedure Incomplete Stent Apposition(Post-procedure)
  • Myocardial Infarction (MI)(12 months)
  • All-cause Mortality(12 months)
  • Target Lesion Revascularization (TLR)(12 Months)
  • Target Vessel Revascularization (TVR)(12 months)
  • Target Lesion Failure (TLF)(12 months)
  • Target Vessel Failure (TVF)(12 months)
  • Definite + Probable Stent Thrombosis Based on Academic Research Consortium (ARC) Definition(>30 days-1 year)
  • Clinical Procedural Success(Duration of hospital stay (usually 1-2 days))
  • Technical Success(Acute-At time of index procedure)
  • Target Lesion Revascularization (TLR)(30 Days)
  • Target Vessel Revascularization (TVR)(30 Days)
  • Definite + Probable Stent Thrombosis Based on Academic Research Consortium (ARC) Definition(24 hours)
  • Definite + Probable Stent Thrombosis Based on Academic Research Consortium (ARC) Definition(>24 hr-30 days)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (17)

Loading locations...

Similar Trials

Completed
Phase 3
EVOLVE II QCA: A Prospective, Multicenter Trial to Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)Atherosclerotic Lesion(s)
NCT01787799Boston Scientific Corporation100
Completed
Not Applicable
The Implementation of Intravascular Ultrasound and Fractional Flow Reserve in the Percutaneous Treatment of Very Long Coronary Artery LesionsCoronary Artery Disease
NCT05621421Vilnius University Hospital Santaros Klinikos80
Recruiting
Not Applicable
IVUS Analysis for Coronary Obstruction in TAVICoronary Artery Occlusion
NCT05164796Universita di Verona100
Terminated
Phase 2
EXCimEr Laser for Long lENgTh Lesions in Below-The-Knee Arteries StudyPeripheral Arterial Occlusive Disease
NCT00718991Flanders Medical Research Program14
Completed
Not Applicable
Investigating the Safety and Efficacy of the Treatment With Luminor DCB and Angiolite DES of iVascular in TASC C and D Tibial Occlusive Disease in Patients With Critical Limb IschemiaCritical Limb Ischemia
NCT04073121Singapore General Hospital50